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Abstract
Introduction: Endothelin-1, a vasoconstrictor peptide, influences cartilage metabolism mainly via endothelin
receptor type A (ETA). Along with the inflammatory nonapeptide vasodilator bradykinin (BK), which acts via
bradykinin receptor B1 (BKB1) in chronic inflammatory conditions, these vasoactive factors potentiate joint pain and
inflammation. We describe a preclinical study of the efficacy of treatment of surgically induced osteoarthritis with
ETA and/or BKB1 specific peptide antagonists. We hypothesize that antagonism of both receptors will diminish
osteoarthritis progress and articular nociception in a synergistic manner.
Methods: Osteoarthritis was surgically induced in male rats by transection of the right anterior cruciate ligament.
Animals were subsequently treated with weekly intra-articular injections of specific peptide antagonists of ETA
and/or BKB1. Hind limb nociception was measured by static weight bearing biweekly for two months post-
operatively. Post-mortem, right knee joints were analyzed radiologically by X-ray and magnetic resonance, and
histologically by the OARSI histopathology assessment system.
Results: Single local BKB1 antagonist treatment diminished overall hind limb nociception, and accelerated
post-operative recovery after disease induction. Both ETA and/or BKB1 antagonist treatments protected joint
radiomorphology and histomorphology. Dual ETA/BKB1 antagonism was slightly more protective, as measured by
radiology and histology.
Conclusions: BKB1 antagonism improves nociceptive tolerance, and both ETA and/or BKB1 antagonism prevents
joint cartilage degradation in a surgical model of osteoarthritis. Therefore, they represent a novel therapeutic
strategy: specific receptor antagonism may prove beneficial in disease management.
Introduction
Osteoarthritis (OA) is characterized by a progressive
destruction of articular cartilage accompanied by sub-
chondral bone remodeling, osteophyte formation, and
synovial membrane inflammation [1]. Clinically, this dis-
ease progresses slowly and principally affects the hands
and large weight-bearing joints. Pain is the primary
complaint of patients with OA. Its etiology is multifac-
torial: subchondral bone can have micro-fractures,
osteophytes can cause stretching of peri-osteal nerve
endings, ligaments may be stretched, the joint capsule
can be inflamed or distended, the synovium may be
inflamed, and muscles may spasm [2]. Furthermore,
neo-innervation of joint tissue concurrent with angio-
genesis [3,4] may contribute to deep joint pain. Further
understanding of the molecular mechanisms behind
these effects should provide avenues towards targeted
disease-modifying or -slowing treatments [5,6].
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21-amino-acid potent vasoconstrictor peptide, plays a
major role in OA pathogenesis. It reduces cartilage ana-
bolism by inhibiting collagen and proteoglycan synthesis
[7]. It causes matrix metalloproteinases one and thirteen
to be synthesized and activated in OA cartilage [8]. ET-
1 also causes excessive production of nitric oxide, which
is generated as the result of an increase in inducible
nitric oxide synthase levels [9]. These effects occur
mainly via endothelin receptor type A (ETA) [10]: it is
expressed in articular tissue by chondrocytes, synovio-
cytes, and endothelial cells, where it plays a significant
role in cartilage and bone metabolism [11,12]; ETA also
potentiates inflammatory joint pain induced by ET-1
[13,14].
ET-1 affects vascular homeostasis via the renin-angio-
tensin-aldosterone system [15]. Through cross-talk with
the kallikrein-kinin system [16], it can also mediate
kinin-induced pain and inflammation. Bradykinin (BK),
the inflammatory nonapeptide vasodilator, has also been
implicated in OA pain and inflammation. It is generated
in OA synovium, as in all inflamed tissue; it also is
released due to the increased vascular pressure in sub-
chondral bone [17]. BK binds two receptors, bradykinin
receptor B1 (BKB1) and bradykinin receptor B2 (BKB2).
The effects of BK in OA occur largely via BKB1, a
receptor implicated in articular nociception [18,19] and
pro-inflammatory reactions [20]. BKB1 also potentiates
the effects of other pro-inflammatory mediators such as
cytokines and prostaglandins. BKB2, though it has been
implicated in nociceptor sensitization in OA [17,19],
may be less relevant as a therapeutic target in the con-
text of a chronic inflammatory response. It is constitu-
tively expressed to a large extent, and is primarily
involved in the acute phase of inflammation [21,22]. In
contrast, BKB1 is up-regulated in chronic inflammatory
conditions, its expression often induced secondary to
inflammatory mediator release [22-24].
Antagonism of ETA and/or BKB1 may represent a
novel therapeutic option to alleviate, and perhaps prevent
or reverse, the pain, inflammation, and tissue damage
that occur as OA progresses from an acute to a chronic
state. We hypothesize that ETA and BKB1 antagonism
will diminish OA progress in a synergistic manner. In the
present work, we describe a preclinical study of the effi-
cacy of treatment of surgically induced OA with ETA
and/or BKB1 peptide antagonists, using an established
rat model of the disease. We found that BKB1 antagonist
treatment diminished hind limb nociception, and both
ETA and/or BKB1 antagonism protected joint radiomor-
phology and histomorphology. This demonstrates that
ETA and BKB1 receptor expression is involved in OA
pathogenesis, and that specific receptor antagonism may
prove beneficial in OA disease management.
Materials and methods
Rat model of osteoarthritis
Animals
Eight-week-old male Lewis rats were purchased from
Charles River Canada (Saint-Constant, Quebec) and
housed under standard conditions. All procedures were
approved by the Sainte-Justine Hospital Research Centre
animal ethics committee and conformed to Canadian
Council on Animal Care guidelines [25].
Study design
The study was conducted as a fractional factorial experi-
ment. Animals were randomly assigned to one of three
surgery conditions: anterior cruciate ligament transec-
tion (ACLT), sham surgery, or no surgery (negative con-
trol). Subsequently, animals were assigned to one of
four treatment groups, as detailed below (Table 1). Sam-
ple size was n = 6 per group.
Surgical technique
OA was induced by surgical transection of the right ante-
rior cruciate ligament. The procedure was modified from
previously published reports [26-29], and is described in
detail in Additional file 1. Briefly, animals were anaesthe-
tized and subjected to either anterior cruciate ligament
transection or sham surgery. One group of animals, kept
as negative controls, were not operated upon.
Drug treatment
Over the course of two months post-operatively, animals
were treated by weekly intra-articular injections of ETA
and/or BKB1 specific peptide antagonists: BQ-123 (ETA
antagonist; Sigma-Aldrich, Oakville, Ontario) [30,31], R-954
(BKB1 antagonist; a kind gift from Pierre Sirois, IPS Théra-
peutique, Sherbrooke, Quebec) [32,33], both, or saline vehi-
c l e ,w a si n j e c t e di n t ot h er i g h tk n e ea tad o s eo f3 0n m o li n
a volume of 50 μL. Injections were performed under iso-
flurane anaesthesia, using a 28G needle; the procedure is
described in detail in Additional file 1. Chemical structures
of the antagonists are depicted in Additional file 2. Doses
were based upon previously published reports [14,19].
Static weight bearing
Over the course of the study, animal nociception
was evaluated biweekly by the static weight bearing test.
Table 1 Experimental groups
Group number Surgery Treatment
1 None Saline
2 Sham Saline
3 ACLT Saline
4 ACLT BQ-123
5 ACLT R-954
6 ACLT BQ-123+R-954
Six experimental groups were designated in the fractional factorial study, with
six subjects per group.
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neered from previously published reports [34-36],
designed, and machined by Usinage FB (Le Gardeur,
Quebec). Design diagrams and photos are appended in
Additional files 3 and 4.
After conditioning, animals were introduced to the
apparatus and restrained in a plexiglass chamber with
an angled base, such that each hind paw rested on a
separate force plate connected to a load cell. The weight
in grams distributed on each hind limb was recorded by
a computer software interface (Futek USB software
interface version 2.10). The static weight bearing distri-
bution of each animal was recorded for 30 seconds;
each data point was then taken as the mean of three 30-
second readings. Data were transferred off-line to a per-
sonal computer, and the weight bearing on the right
hind limb as a percentage of total weight bearing on
both hind limbs was calculated by the following equa-
tion [37]:
% Weight on right leg =
Weight on right leg
Weight on right leg +W e i ght on left leg
× 100
All values are given as mean ± standard deviation (SD)
per experimental group.
Statistics
Static weight bearing data were analyzed by repeated
measures analysis of variance (ANOVA), which com-
pares the global differences between groups of response
profiles measured on the same subjects repeatedly over
the course of the study [38,39]. Test values were taken
as the dependent variable and treatment group as the
independent variable, with the animal as the grouping
factor. Sphericity was confirmed with Mauchly’s W test.
Tukey multiple comparisons testing was used to estab-
lish significance in between groups, with directionality
taken from the sign of the mean difference. P-values less
than 0.05 were considered statistically significant. Ana-
lyses were conducted using R (version 2.12.1) [40].
Euthanasia and sample preparation
At four or eight weeks post-surgery, animals were sacri-
ficed by cardiac puncture under deep isoflurane anaes-
thesia. The right knee was dissected, and 40-mm-long
s a m p l e sw e r ec u ta n ds t o r e di np h o s p h a t e - b u f f e r e ds a l -
ine until imaged by digital micro-X-ray (DX) and/or
micro-magnetic resonance (MR). Samples were dissected
the same day as the radiological scans.
Digital micro-X-ray
All knee samples were X-rayed using a Faxitron MX-20
specimen X-ray system (Faxitron X-Ray Corporation,
Lincolnshire, IL). Anteroposterior and lateral views were
acquired at 5 × magnification (10 × 10 μmp i x e ls i z e )
using a dose of 26 kV for 6 seconds. Images were
analyzed using OsiriX software (version 3.7.1) [41]. Radi-
ological evidence of joint degradation was scored by two
blinded examiners using an OA radiological score modi-
fied from Clark et al. [42] and Esser et al. [43]. Bone
demineralization, subchondral bone erosion, and hetero-
topic ossification were all scored on a scale from zero
(normal) to three (marked degenerative changes). Total
scores were calculated by summing the individual scores
for each index, with a maximum possible score of nine.
Statistics
OA radiological scores were statistically analyzed by
one-way ANOVA, with total scores taken as the depen-
dent variable and treatment group as the independent
variable. Pairwise post-hoc testing with Holm correction
was used to establish significance in between treatment
groups. P-values less than 0.05 were considered statisti-
cally significant. Analyses were conducted using R (ver-
sion 2.12.1) [40].
Micro-magnetic resonance imaging
Image acquisition
A subset of animals were sacrificed four weeks post-
operatively and their right knees were imaged by micro-
MR. Imaging was performed using a Bruker PharmaS-
can (Ettlingen, Germany) 7 Tesla MR scanner at the
McGill University Small Animal Imaging Lab (Montreal,
Quebec). Knee samples were placed in a custom-made
support inside a 15-mL centrifuge tube, which was then
filled with the MR-inert buffer FC-770 (3M Fluorinert
Electronic Liquid). Samples were introduced into a
1H
mouse brain radio frequency (RF) coil (inner diameter
22 mm), and centered in the magnet. The RF coil was
tuned and matched to the sample, and the magnet was
then shimmed. The system was controlled via Bruker
ParaVision software (version 5.0).
Positioning was confirmed with a tri-pilot rapid scan,
which was then used to place 14 coronal slices for two-
dimensional anatomical scanning of the joint using a
rapid acquisition with relaxation enhancement (RARE)
multiecho spin echo pulse sequence (TurboRARE). Scan
parameters were as follows: repetition time (TR) = 3500
milliseconds (ms), echo time (TE) = 36 ms, echo train
length (ETL) = 8, slice thickness = 500 μm, acquisition
matrix = 384 × 384, and number of averages = 4. Voxel
size was 140.1¯ 6 × 140.1¯ 6 × 500 µm. These scans were
then repeated in the sagittal projection.
Once these scans were acquired, one 1-mm-thick axial
slice was placed in the center of the knee joint in order to
scan the articular cartilage with a series of multislice mul-
tiecho (MSME) T2-weighted pulse sequences. Scan para-
meters were TR = 3500 ms, ETL = 1, acquisition matrix =
192 × 256, with voxel size of 156.25 × 156.25 × 1000 μm.
16 different TE were used: 10, 20, 30, 40, 50, 60, 70, 80,
90, 100, 110, 120, 130, 140, 150, and 160 ms.
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sequences were based on previously published reports
[44].
Image processing and analysis
After acquisition, images were analyzed using OsiriX
software (version 3.7.1) [41]. Anatomical TurboRARE
images were examined for correct depiction of anatomi-
cal features of the knee joint, and to confirm ACLT
where applicable. As well, images were analyzed for
signs of cartilage decay, indicated by lower signal inten-
sity of the articular surfaces. The MSME-T2 images
were aligned into an image stack, and regions of inter-
est, corresponding to the articular cartilage, were manu-
ally drawn and propagated throughout the stack. A
mean T2 fit map was then automatically generated by
fitting the signal intensity to the spin-spin relaxation sig-
nal decay equation:
S(TE)=M0 exp−

TE
T2

where signal intensity S is defined as a function of
echo time TE, and is related to the spin density M0 and
the transverse relaxation time T2. The equation was
solved for the mean T2 value over the 16-image stack by
using least-squares single-exponential curve-fitting, with
initial guesses of M0 = signal intensity at 10 ms and T2
= 30 ms, in order to guarantee rapid convergence [44].
OsiriX then generated a T2 fit map graph with regres-
sion line and values for T2 and M0.
Histology
After radiological examination, knee samples were fixed in
10% neutral buffered formalin for two weeks, decalcified
with RDO Rapid Decalcifier (Apex Engineering Products,
Aurora, Illinois) for three days, circulated, and embedded
in paraffin. Five-micron sagittal sections were acquired
from the middle of the knee joint. Histomorphological
staining was performed as previously described [45]: slides
were deparaffinized, rehydrated, stained with Safranin O
(which colors proteoglycans red), counterstained with Fast
Green FCF (which colors proteins green) and with Wei-
gert’s hematoxylin (which colors nuclei black), dehydrated,
cleared, and mounted in Permount. Representative digital
photomicrographs were acquired with a Leica DM R
microscope (Wetzlar, Germany) fitted with a QImaging
Retiga 1300 B camera (Surrey, British Columbia), con-
trolled by QCapture software (version 2.95.0). Images
were captured at 50 × (low-power) or 200 × (high-power)
magnification, and subsequently color-matched and
balanced using Adobe Photoshop CS3.
Histopathological scoring
Four slides from each condition were scored by two
blinded examiners using the Osteoarthritis Research
Society International (OARSI) histopathology assessment
system [46], which assigns numeric values to grade, or
depth progression into cartilage (0-6), and stage, or
extent of joint involvement (0-4); multiplying grade and
stage yields a total OA score with a maximum value of
24. Scores were averaged in between the two examiners;
inter-examiner variation was within ± 5%.
Statistics
OARSI scores were statistically analyzed by one-way
ANOVA, with total scores taken as the dependent vari-
able and treatment group as the independent variable.
Pairwise post-hoc testing with Holm correction was
used to establish significance in between treatment
groups. P-values less than 0.05 were considered statisti-
cally significant. Analyses were conducted using R (ver-
sion 2.12.1) [40].
Immunohistochemistry
Additional 5-micron sections were processed for immu-
nohistochemical detection of type II collagen. Slides
were deparaffinized, rehydrated, and washed in phos-
phate-buffered saline (PBS). Sections were incubated in
2 mg/mL hyaluronidase for 30 minutes at 37°C, followed
by permeabilization with 0.3% Triton X-100 for 30 min-
utes at room temperature. Endogenous peroxidase activ-
ity was then quenched with 2% hydrogen peroxide in
PBS for 15 minutes. Sections were blocked with normal
mouse serum (Vector Laboratories, Burlingame, Califor-
nia) for 1 hour, after which they were blotted and then
incubated with monoclonal mouse anti-rat type II col-
lagen (clone SPM239; Spring Bioscience, Pleasanton,
California) for 18 hours at 4°C. Sections were then
washed in PBS, incubated with biotinylated anti-mouse
IgG (Vector) for 1 hour at room temperature, and
stained using the avidin-biotin complex method (Vectas-
tain ABC kit; Vector). Color was developed using 3,3’-
diaminobenzidine (Dako Diagnostics, Mississauga,
Ontario) containing hydrogen peroxide. Slides were
counterstained with Harris modified hematoxylin, dehy-
drated, cleared, mounted, and examined by light micro-
scopy as described above.
Results
ETA and BKB1 antagonism ameliorates OA nociceptive
tolerance
To determine the effects of ETA and/or BKB1 local
antagonist treatment on nociception in a surgical OA
model, the static weight bearing asymmetry of the ani-
mals was measured repeatedly over the course of the
study (Figure 1). Pre-operative baseline values for all
groups indicated hind limb weight bearing symmetry
(49.89 ± 0.42%). Unoperated vehicle-treated animals
showed no important changes in hind limb weight bear-
ing from baseline pre-operative values over the course
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distribution. Sham-operated vehicle-treated animals dis-
played an initial weight bearing imbalance 14 days post-
operatively (36.47 ± 1.12%), but recovered weight bear-
ing symmetry quickly thereafter (44.84 ± 0.33% by day
26 post-operatively). ACLT saline-treated animals
showed significant weight bearing imbalance two weeks
post-operatively, down to 33.66 ± 2.05% weight on the
right leg, suggesting severe nociception. All animals had
similar nociceptive tolerance at the last measured time-
point (day 50 post-operatively), indicating nociceptive
adaptation, but drug-treated animals were able to
recover faster than saline-treated animals (up to 40.54 ±
3.36% weight on right leg by day 40 post-operatively, for
BQ-123 and R-954 dual treatment).
Repeated measures analysis of variance of the static
weight bearing data, followed by Tukey post-hoc
hypothesis tests (Table 2), demonstrated that treatment
with R-954, or both BQ-123 and R-954, significantly
ameliorated nociceptive tolerance in ACLT animals over
the study period, as compared to saline-treated positive
controls (0.0001 ≤ P ≤ 0.0002). When administered
alone, BQ-123 did not result in statistically significant
increased nociceptive tolerance (P = 0.1847). Sham sur-
gery was found to be slightly less nociceptive than ACL
transection (P = 0.019), confirming that ACLT is neces-
sary for a maximal nociceptive response. Furthermore,
nociception in the sham-operated animals was compar-
able to unoperated animals, with no statistically signifi-
cant difference calculated (P = 0.8746).
Antagonist treatment improved radiological indices of OA
R i g h tk n e ej o i n t sw e r ed i s s e c t e da tt h ee n do ft h es t u d y
period and imaged by DX (Figure 2) and MR (Figure 3) to
examine the radiological effects of antagonist treatments.
ACLT rapidly induced radiological evidence of OA: knee
joints showed signs of degradation such as subchondral
bone remodeling, osteophyte formation (Figure 2c and
Table 3), cartilage layer thinning (Figure 3c), and length-
ened cartilage T2 (Table 4). Neither sham surgery nor
intra-articular injection affected joint radiomorphology
(Figures 2a,b and 3a,b). DX analysis of antagonist-treated
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Figure 1 ETA and/or BKB1 antagonist treatment improves static weight bearing tolerance. Static weight bearing tolerance was measured
repeatedly at defined time points over the course of the study. Data are presented as mean ± SD per experimental group (n = 6), of weight on
the right leg as a percentage of total weight on both hind limbs. Day 0, baseline pre-operative values. Repeated measures analysis of variance
with Tukey post-hoc (Table 2) indicated that BKB1 antagonist treatment significantly ameliorated nociceptive tolerance in ACLT animals over the
study period, as compared to saline-treated positive controls.
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Page 5 of 11knee joints showed less subchondral bone remodeling and
heterotopic ossification than saline-treated animals (Figure
2d,e,f and Table 3). Dual ETA/BKB1 antagonism appeared
to be slightly more protective than single antagonism: less
subchondral bone remodeling and greater trabecular
integrity was observed in the dual-antagonist-treated ani-
mals than in the single-antagonist-treated animals. Radi-
ological scoring of the DX views for a panel of OA joint
degenerative changes (Table 3 and Additional file 5)
demonstrated that treatment with BQ-123, R-954, or both,
significantly ameliorated radiological indices of disease
progression in ACLT animals, as compared to saline-trea-
ted positive controls (0.0020 ≤ P ≤ 0.0214, one-way
ANOVA with Holm post-hoc). MR analysis of knee joints
revealed that antagonist-treated animals had greater
cartilage thickness and fewer cartilage lesions (Figure 3d,e,
f), as well as shorter cartilage T2 (Table 4, statistical signifi-
cance not achieved) than saline-treated ACLT animals.
These data suggest that antagonist treatment protected
joint radiomorphology after ACLT.
Antagonism protects joint histomorphology
To investigate the effects of ETA and/or BKB1 antago-
nist treatment on histological indices of disease, rat
knee joints were processed to assess cartilage proteogly-
can content and joint histomorphology (Figure 4 left
and middle columns). ACLT saline-treated animals lost
most proteoglycan staining when examined at eight
weeks post-operatively, with severe articular surface dis-
ruptions and osteophyte formation (Figure 4g,h). In
contrast, cartilage proteoglycans were detected in the
knees of ETA and/or BKB1 antagonist-treated animals
(Figures 4j,k,m,n and 4p,q), indicating that treatment
protects cartilage structural components. As well,
articular surface integrity was preserved to a greater
extent, with dual antagonism appearing to be most pro-
tective (Figure 4p,q). Neither sham surgery nor intra-
articular injection of saline vehicle negatively affected
joint histomorphology (Figures 4a,b and 4d,e). Mean
OARSI scores (Table 5 and Additional file 6) indicate
that ETA and/or BKB1 antagonist treatment signifi-
cantly reduced the amount of affected joint tissue and
the degree of histopathology, as compared to saline-
treated positive controls (P < 0.0001 for all compari-
sons, one-way ANOVA with Holm post-hoc).
Table 2 Static weight bearing post-hoc tests
Contrast Estimate Standard
error
z-score P(>|z|)
None/Saline vs Sham/Saline - 5.1697 1.9903 - 2.597 0.8746
Sham/Saline vs ACLT/Saline 6.5667 2.0155 3.258 0.019
ACLT/BQ-123 vs
ACLT/Saline
2.5845 1.8841 1.372 0.1847
ACLT/R-954 vs ACLT/Saline 0.6951 1.9669 0.353 0.0002
ACLT/BQ-123+R-954 vs
ACLT/Saline
0.2784 1.8503 0.15 0.0001
Tukey post-hoc tests were conducted following repeated measures ANOVA of
the static weight bearing data. From left to right, the table columns present
the contrast of interest, the parameter estimate from the linear matrix model,
the standard error of that estimate, the standard z-score, and the associated
P-value.
Figure 2 Antagonist treatment improves radiological indices of OA: X-ray results. (a) No surgery and saline treatment; (b) sham surgery
and saline treatment; (c) ACLT and saline treatment; (d) ACLT and BQ-123 treatment; (e) ACLT and R-954 treatment; (f) ACLT and BQ-123+R-954
dual treatment. Blue arrows indicate tibial plateau, purple arrows indicate subchondral bone, and green arrows indicate osteophytes. Sagittal
views. Scale bar, 1 cm.
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Page 6 of 11Type II collagen, the major structural collagen of car-
tilage, was detected by immunohistochemistry (Figure 4
right column). ACLT saline-treated animals displayed
significant losses of articular surface type II collagen
(Figure 4i) with some localization in the deep zones of
cartilage, reflecting cartilage remodeling processes. Ani-
mals treated with ETA and/or BKB1 antagonists (Figure
4l,o,r) displayed varying degrees of protection, retaining
some type II collagen staining. Neither sham surgery
nor intra-articular injection of saline vehicle negatively
affected joint type II collagen expression (Figures 4c and
4f): protein was localized in the superficial zone of
articular cartilage, indicating functional joint tissue.
Discussion
In the present study, we investigated whether antagon-
ism of ETA and/or BKB1 could slow and/or prevent
osteoarthritic cartilage degradation and joint nociception
in a rat surgical model of OA. We provide several lines
of evidence that suggest protective effects of ETA and/
or BKB1 antagonism in vivo: BKB1 antagonist treatment
improved hind limb nociceptive tolerance, and both
ETA and/or BKB1 antagonist treatment ameliorated
radiological indices of disease, and protected articular
cartilage and bone histomorphometry.
The most interesting finding of our study is that noci-
ceptive tolerance was augmented in our model after
BKB1 antagonist treatment, with faster post-operative
recovery than vehicle-treated controls. These results are
consistent with other reports [19], where local treatment
with BKB1 receptor antagonists reduced overt acute
joint nociception. We extend this finding to the dual
antagonist treatment approach to male animals in a
model of chronic pain, as well as relating it to measures
of joint integrity by radiology and histology. Low-grade
joint pain is the most common reason for patient pre-
sentation, and is often the major debilitating factor in
OA cases [47,48]. Thus, the anti-nociceptive effects of
Figure 3 Antagonist treatment improves radiological indices of OA: MR results. (a) No surgery and saline treatment; (b) sham surgery and
saline treatment; (c) ACLT and saline treatment; (d) ACLT and BQ-123 treatment; (e) ACLT and R-954 treatment; (f) ACLT and BQ-123+R-954 dual
treatment. Red arrows indicate articular cartilage. Sagittal views. Scale bar, 1 cm.
Table 3 OA radiological scores
Group
number
Surgery Treatment Mean total radiological
score
SD
1 None Saline 0.25 0.50
2 Sham Saline 1.16 0.75
3 ACLT Saline 4.86 1.68
4 ACLT BQ-123 2.83 1.47
a
5 ACLT R-954 2.50 1.22
b
6 ACLT BQ-123+R-
954
2.67 1.03
c
Radiological scoring of the DX views of the knee joints [42,43] indicated that
antagonist treatment protected joint radiomorphology after ACLT. One-way
ANOVA with Holm post-hoc:
aP = 0.0214, ACLT/BQ-123 treatment versus
ACLT/saline treatment;
bP = 0.0020, ACLT/R-954 treatment versus ACLT/saline
treatment;
cP = 0.0125, ACLT/BQ-123+R-954 dual treatment versus ACLT/saline
treatment.
Table 4 Cartilage mean T2 values
Group number Surgery Treatment Mean T2 value (ms)
1 None Saline 51.60
2 Sham Saline 52.12
3 ACLT Saline 64.38
4 ACLT BQ-123 63.23
5 ACLT R-954 61.13
6 ACLT BQ-123+R-954 56.57
Cartilage mean T2 values in milliseconds were calculated for all conditions
using OsiriX software (version 3.7.1) [41]. Statistical significance in between
groups was not achieved.
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Page 7 of 11Figure 4 Antagonist treatment protects joint histomorphometry. Sagittal sections. Left and middle columns, Safranin O/Fast Green FCF
staining. Right column, type II collagen immunohistochemistry. Left column, low-power magnification: scale bar, 200 μm; original magnification
50 ×. Middle and right columns, high-power magnification: scale bar, 50 μ m; original magnification 200 ×. Conditions by rows: (a), (b), (c) no
surgery and saline treatment; (d), (e), (f) sham surgery and saline treatment; (g), (h), (i) ACLT and saline treatment; (j), (k), (l) ACLT and BQ-123
treatment; (m), (n), (o) ACLT and R-954 treatment; (p), (q), (r) ACLT and BQ-123+R-954 dual treatment. Yellow arrows indicate loss of Safranin O
staining, purple arrows indicate cartilage notching, and red arrow indicates an osteophyte. Black arrows indicate type II collagen immunostaining.
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Page 8 of 11BKB1 antagonism make this treatment strategy attrac-
tive. Surprisingly, single ETA antagonism was relatively
ineffective at diminishing joint nociception in our
model. This finding, which contradicts our initial
hypothesis, suggests that ETA potentiation of ET-1-
induced joint pain [14] may not be direct, especially in a
chronic inflammatory state.
W ef o u n dt h a ts i n g l ea n dd u a lE T A / B K B 1a n t a g o n i s t
treatments decreased radiological disease indices, in
terms of osteophyte formation, cartilage thinning, and
subchondral bone remodeling, with dual antagonism
being most protective. As well, cartilage T2, increased in
ACLT animals, was decreased by antagonist treatment,
which indicates a cartilage-preserving effect. Longer car-
tilage transverse relaxation times are an indicator of car-
tilage degradation; this MR parameter is indicative of
cartilage composition and integrity [49-51]. Radiographic
evidence is the main criterion for OA diagnosis and pro-
gression [52,53]. The most common clinical diagnostic
test is via X-ray of the affected joint: joint space narrow-
ing as measured on X-ray is often used as a longitudinal
marker of disease evolution. It is difficult to directly
compare radiological parameters between human and
rat knees due to the quadrupedal nature of the animal
and the markedly different radiological anatomy that
this entails [54]. However, we were able to detect radi-
ological evidence of OA progression in ACLT animals,
as has been described in similar studies [44,55].
OA induction in rat knees leads to a rapid decrease in
cartilage proteoglycan staining, along with articular sur-
face disruption and osteophyte formation [26,27]. ETA/
BKB1 antagonist treatment protected the proteoglycan
content of the joint and preserved articular surface
integrity. Furthermore, there was some protection of
type II collagen protein expression. This allowed the
joint cartilage to retain its normal biophysical properties,
as cartilage proteoglycans are responsible, along with
collagen, for retaining water in the tissue, which pro-
vides spring and resilience [56,57]. These findings likely
suggest that the protection of cartilage proteoglycans,
collagens, and articular surface histomorphology may be
one explanation for the increased pain tolerance
observed in antagonist-treated animals; our results con-
cur with those of other reports, which correlated the
preservation of articular cartilage proteoglycan staining
with pain tolerance behavior [26].
The ET-1 and BK systems are involved in joint tissue
inflammation and nociception, concomitant with pro-
inflammatory mediators. However, exploration of potential
therapeutic targets in these systems has been modest: the
main classes of disease-modifying osteoarthritis drugs cur-
rently in development include cytokine and matrix metal-
loproteinase inhibitors, anti-resorptives, and growth factors
[58]. To our knowledge, the only clinical trial of a drug tar-
geting a vasoactive factor in OA is the bradykinin receptor
B2 antagonist Icatibant, by Sanofi-Aventis [59]. This drug
is no longer in clinical development [60], due to mixed
results: while it provided local analgesia in knee OA, no
anti-inflammatory effect could be detected [61]. Our results
suggest that ETA and BKB1 represent novel therapeutic
targets in OA. Specific receptor antagonists could be tested
in clinical trials for OA pain and tissue damage.
Conclusions
Using a rat surgically induced model of OA, we demon-
strated that local treatment with specific peptide antago-
nists of ETA and/or BKB1 may slow or stabilize the
development of radiomorphological and histomorphologi-
cal changes occurring in OA pathogenesis. Furthermore,
we showed that BKB1 antagonist treatment accelerated
recovery of, and improved longitudinally, nociceptive tol-
erance in ACLT animals. Taken together, our results indi-
cate that blocking ETA and BKB1 improves OA
prognostic indices, which implies that defective signaling
might play a role in chronic OA pain. Our results also
raise the possibility of targeted receptor antagonism as a
relevant therapeutic option. Further studies are required
to understand the mechanisms underlying the exact nat-
ure of receptor cross-regulation and synergism.
Additional material
Additional file 1: Rat anterior cruciate ligament transection and
intra-articular injection. Detailed descriptions and macro photographs
of rat anterior cruciate ligament transection and intra-articular injection.
PDF file named Rat ACLT and IA injection.pdf (3 pages).
Additional file 2: Chemical structures of BQ-123 and R-954.2 D
chemical structures of selective ETA peptide antagonist BQ-123 (left) and
selective BKB1 peptide antagonist R-954 (right). PDF file named
antagonist structures.pdf (1 page).
Additional file 3: Design diagrams for static weight bearing
apparatus. Original design diagrams for static weight bearing apparatus.
Labels in French. Auto-drafted using CATIA V5 R19. PDF file named
static weight bearing apparatus design diagrams.pdf
(4 pages).
Table 5 OARSI histopathology scores
Group number Surgery Treatment Mean OARSI score SD
1 None Saline 0.43 0.53
2 Sham Saline 0.50 1.00
3 ACLT Saline 17.00 5.77
4 ACLT BQ-123 4.75 0.96
a
5 ACLT R-954 4.25 2.02
b
6 ACLT BQ-123+R-954 3.50 2.89
c
Four slides per condition were scored by two blinded examiners using the
OARSI histopathology assessment system [46]. Results were averaged and are
presented as mean scores per condition. Inter-examiner variation was within
± 5%. One-way ANOVA with Holm post-hoc:
aP = 0.000017, ACLT/BQ-123
treatment versus ACLT/saline treatment;
bP = 0.00001, ACLT/R-954 treatment
versus ACLT/saline treatment;
cP = 0.0000048, ACLT/BQ-123+R-954 dual
treatment versus ACLT/saline treatment.
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Page 9 of 11Additional file 4: Static weight bearing apparatus in use. Static
weight bearing apparatus with rat positioned for measurements. A, side
view; B, angle view; C, front view. PDF file named static weight
bearing apparatus photos.pdf (1 page).
Additional file 5: OA radiological scores. Unblinded raw data for the
OA radiological scores, presented as averaged scores for each parameter.
CSV file named radiological scores.csv.
Additional file 6: OARSI histopathology scores. Unblinded raw data
for the OARSI histopathology scores, presented as averaged scores for
each parameter. CSV file named OARSI scores.csv.
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